# A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

> **NCT03954106** · PHASE2 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- DLBCL
- Neurotoxicity Syndromes

## Interventions

- **DRUG:** Defibrotide

## Key facts

- **NCT ID:** NCT03954106
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-04
- **Primary completion:** 2020-09-18
- **Final completion:** 2020-09-30
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20 efficacy evaluable patients.
- **Last updated:** 2021-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03954106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03954106, "A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03954106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*